Epigral Share Price

Epigral Limited was erstwhile incorporated as Meghmani Finechem Limited in 2007, which is engaged in manufacturing and selling of Chlor Alkali its Derivatives and also in Trading of Agrochemical products. The Company was incorporated as a subsidiary of Meghmani Organics Limited. Meghmani Finechem Limited (MFL) was demerged from Meghmani Organics Limited (MOL) as a going concern, through the Scheme of Arrangement for Demerger and the said Scheme became effective from May 10, 2021. The ChlorAlkali business commissioned in 2009, growing from an installed capacity of 1,88,000 TPA in 2015 to 3,15,000 TPA at the close of FY 202021. The Company is now among the leading players in Indias chlor alkali industry. In terms of the said Scheme, the Company allotted 2,39,03,029 Equity Shares of Rs 10/ each on 20th May, 2021 to the shareholders of Meghmani Organics Limited.The Company grew its business following the commissioning of new plants (Caustic Soda, Hydrogen Peroxide and the 36 MW Captive Power Plant). The timely commissioning of the plants represented the faith of the management in the longterm potential of the sector and country. The Caustic Soda capacity was expanded by 1,27,000 TPA to 2,94,000 TPA and commissioned in June 2020. The Captive Power Plant capacity was increased by 36 MW to 96 MW, commissioned in June 2020. The Company commissioned a 60,000 TPA Hydrogen Peroxide plant in July 2020. The Company further commissioned the capacity expansion of Caustic Soda manufacturing facility to 400 KTPA by adding 106 KTPA facility, along with expansion of 36 MW Captive Power Plant on 30th September, 2022. It commissioned Epichlorohydrin (ECH) manufacturing facility with a capacity of 50,000 TPA on 1st June, 2022, which is used in varied applications, such as Epoxy Resin, Water Treatment Chemicals, Textiles, Pharmaceuticals, Paper Reinforcement, Synthetic Glycerine, etc. It commissioned CPVC Resinmanufacturing facility with a capacity of 30,000 TPA capacity on 18th July, 2022.In 202425, Company commissioned additional capacity of 45,000 TPA of CPVC Resin facility in April, 2024, reaching total capacity of CPVC Resin to 75,000 TPA. It also forward integrated and commissioned CPVC Compound facility of 35,000 TPA in June, 2024. Company has announced expansion of additional 75,000 TPA capacity of CPVC Resin plant at its Dahej facility in Gujarat. With this expansion, Companys total CPVC resin capacity reaches a remarkable 1,50,000 TPA in FY25. Company has commissioned Indias First Chlorotoluenes Value Chain Facility at its Dahej Complex in Gujarat on 24th March, 2025.

Epigral reported a Q1 FY 2025-26 revenue of ₹606.54 crore, up 32.5% YoY, with net profit increased 82.1% to ₹160.41 crore. For the full year FY2025–2026, revenue reached ₹2565.34 crore and profit touched at ₹356.7 crore. As of Sep '25, Epigral’s market capitalisation stood at ₹7,289.59 crores. Shareholding as of Sep '25 shows promoters holding 68.8%, with FIIs at 2.7%, DIIs at 5%, and public at 23.5%.

As of 3 Nov 2025, Epigral share price is ₹1689.7. The stock opened at ₹1681 and had closed at ₹1689.3 the previous day. During today’s trading session, Epigral share price moved between ₹1,681.00 and ₹1,707.80, with an average price for the day of ₹1694.40. Over the last 52 weeks, the stock has recorded a low of ₹1,502.35 and a high of ₹2,242.55. In terms of performance, Epigral share price has declined by 2.6% over the past six months and has declined by 6.76% over the last year.